Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting
April 04, 2017 08:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, April 04, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs
January 03, 2017 09:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced...
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting
December 05, 2016 13:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting
November 03, 2016 09:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today...
Poseida Therapeutics Establishes Scientific Advisory Board
September 08, 2016 07:30 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics,...
Poseida Therapeutics Expands Executive Leadership Team
August 18, 2016 07:30 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics,...
Poseida Therapeutics Announces Series A Financing
December 16, 2015 09:00 ET
|
Poseida Therapeutics, Inc.
LA JOLLA, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a US-based, privately-held, human therapeutics company focused on the development of novel therapies using...
Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies
August 11, 2015 06:00 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered...
Poseida Therapeutics, Inc., Expands Board of Directors
August 05, 2015 16:27 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (Transposagen), announces the...
Poseida Therapeutics to Participate in Jefferies 2015 Healthcare Conference
June 01, 2015 11:15 ET
|
Poseida Therapeutics, Inc.
SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. ("Poseida"), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. ("Transposagen"), announces...